Total Payments
$5,686
2024 Payments
$1,185
Companies
20
Transactions
260
Medicare Patients
863
Medicare Billing
$142,379
Payment Breakdown by Category
Food & Beverage$4,718 (83.0%)
Other$540.00 (9.5%)
Research$300.00 (5.3%)
Education$87.56 (1.5%)
Consulting$40.00 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,718 | 232 | 83.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $540.00 | 14 | 9.5% |
| Unspecified | $300.00 | 2 | 5.3% |
| Education | $87.56 | 11 | 1.5% |
| Consulting Fee | $40.00 | 1 | 0.7% |
Payments by Type
General
$5,386
258 transactions
Research
$300.00
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $995.00 | 69 | $0 (2024) |
| ABBVIE INC. | $891.85 | 35 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $540.00 | 14 | $0 (2017) |
| Celgene Corporation | $536.68 | 38 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $525.85 | 26 | $0 (2024) |
| GlaxoSmithKline, LLC. | $405.27 | 20 | $0 (2024) |
| Radius Health, Inc. | $309.96 | 7 | $0 (2024) |
| PFIZER INC. | $303.44 | 18 | $0 (2024) |
| UCB, Inc. | $277.71 | 10 | $0 (2024) |
| UCB Biosciences Inc. | $250.00 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,185 | 54 | ABBVIE INC. ($478.41) |
| 2023 | $382.57 | 11 | UCB, Inc. ($151.06) |
| 2022 | $308.87 | 13 | ABBVIE INC. ($102.21) |
| 2021 | $512.11 | 34 | AbbVie Inc. ($145.06) |
| 2020 | $257.70 | 9 | Boehringer Ingelheim Pharmaceuticals, Inc. ($155.41) |
| 2019 | $148.90 | 6 | GlaxoSmithKline, LLC. ($40.00) |
| 2018 | $1,149 | 74 | Amgen Inc. ($438.01) |
| 2017 | $1,741 | 59 | SANOFI-AVENTIS U.S. LLC ($540.00) |
All Payment Transactions
260 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $15.95 | General |
| Category: IMMUNOLOGY | ||||||
| 12/20/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $0.70 | General |
| Category: IMMUNOLOGY | ||||||
| 12/11/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $12.37 | General |
| Category: Bone Health | ||||||
| 12/10/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $13.13 | General |
| Category: Immunology | ||||||
| 11/19/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $6.30 | General |
| Category: Inflammation | ||||||
| 11/13/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $31.29 | General |
| Category: Dermatology | ||||||
| 11/07/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $15.54 | General |
| Category: IMMUNOLOGY | ||||||
| 10/28/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $33.47 | General |
| Category: IMMUNOLOGY | ||||||
| 10/24/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $123.86 | General |
| Category: IMMUNOLOGY | ||||||
| 10/23/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $6.22 | General |
| Category: Inflammation | ||||||
| 10/16/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $15.92 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 10/10/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $16.29 | General |
| Category: IMMUNOLOGY | ||||||
| 09/23/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $12.47 | General |
| Category: Inflammation | ||||||
| 09/13/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $8.02 | General |
| Category: IMMUNOLOGY | ||||||
| 09/12/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $9.43 | General |
| Category: Bone Health | ||||||
| 08/27/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $27.26 | General |
| Category: IMMUNOLOGY | ||||||
| 08/26/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $15.77 | General |
| Category: Bone Health | ||||||
| 08/08/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $10.68 | General |
| Category: IMMUNOLOGY | ||||||
| 07/29/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $21.66 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 07/25/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $10.53 | General |
| Category: IMMUNOLOGY | ||||||
| 07/23/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $7.38 | General |
| Category: Inflammation | ||||||
| 07/09/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $27.94 | General |
| Category: IMMUNOLOGY | ||||||
| 07/02/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $23.25 | General |
| Category: IMMUNOLOGY | ||||||
| 06/25/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $13.00 | General |
| Category: IMMUNOLOGY | ||||||
| 06/13/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $15.05 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| National Databank for Rheumatic Diseases Registry Study of Safety in Patients Treated with Certolizumab Pegol and Non-biologic Disease-Modifying Antirheumatic Drug Therapies | UCB Biosciences Inc. | $250.00 | 1 |
| RALLY Abatacpet Safety Registry IM101045B | E.R. Squibb & Sons, L.L.C. | $50.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 197 | 333 | $105,729 | $31,290 |
| 2022 | 10 | 364 | 558 | $166,382 | $51,423 |
| 2021 | 5 | 207 | 324 | $89,748 | $41,253 |
| 2020 | 3 | 95 | 184 | $39,350 | $18,412 |
Total Patients
863
Total Services
1,399
Medicare Billing
$142,379
Procedure Codes
25
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 96 | 207 | $63,953 | $17,380 | 27.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 20 | 33 | $13,288 | $4,650 | 35.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 23 | 23 | $12,448 | $3,938 | 31.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 20 | 20 | $8,204 | $2,225 | 27.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 15 | 20 | $3,769 | $1,571 | 41.7% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 12 | 18 | $3,600 | $1,394 | 38.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 11 | 12 | $468.00 | $132.51 | 28.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 114 | 217 | $66,364 | $20,745 | 31.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 44 | 76 | $32,257 | $10,154 | 31.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 47 | 47 | $26,539 | $7,623 | 28.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 39 | 39 | $16,863 | $4,841 | 28.7% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 16 | 22 | $4,400 | $2,723 | 61.9% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 23 | 29 | $5,833 | $2,226 | 38.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 36 | 40 | $8,159 | $2,170 | 26.6% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2022 | 13 | 13 | $2,600 | $657.65 | 25.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 19 | 19 | $735.00 | $228.09 | 31.0% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2022 | 13 | 56 | $2,632 | $54.56 | 2.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 69 | 160 | $33,132 | $17,910 | 54.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 47 | 65 | $19,084 | $9,502 | 49.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 52 | 52 | $26,008 | $9,378 | 36.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 26 | 34 | $6,293 | $2,622 | 41.7% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 13 | 13 | $5,231 | $1,841 | 35.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 50 | 106 | $21,200 | $9,645 | 45.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 31 | 60 | $15,000 | $7,785 | 51.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 14 | 18 | $3,150 | $982.77 | 31.2% |
About Dr. Lorilee Sutter, M.D
Dr. Lorilee Sutter, M.D is a Rheumatology healthcare provider based in Palm Springs, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1114906435.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lorilee Sutter, M.D has received a total of $5,686 in payments from pharmaceutical and medical device companies, with $1,185 received in 2024. These payments were reported across 260 transactions from 20 companies. The most common payment nature is "Food and Beverage" ($4,718).
As a Medicare-enrolled provider, Sutter has provided services to 863 Medicare beneficiaries, totaling 1,399 services with total Medicare billing of $142,379. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Palm Springs, CA
- Active Since 01/13/2006
- Last Updated 10/15/2024
- Taxonomy Code 207RR0500X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1114906435
Products in Payments
- SYNVISC-ONE (Device) $540.00
- Enbrel (Biological) $539.42
- Otezla (Drug) $536.68
- RINVOQ (Biological) $514.54
- Cimzia (Drug) $407.85
- BENLYSTA (Biological) $405.27
- COSENTYX (Biological) $394.00
- EVENITY (Biological) $308.56
- XELJANZ (Drug) $303.44
- Tymlos (Biological) $221.12
- SKYRIZI (Biological) $215.52
- OFEV (Drug) $141.77
- Humira (Biological) $129.37
- KEVZARA (Drug) $116.02
- Prolia (Biological) $114.92
- ORENCIA (Biological) $50.00
- TAVNEOS (Drug) $32.10
- SAPHNELO (Biological) $31.82
- COSENTYX (Drug) $31.29
- IDACIO (Biological) $29.26
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.